Revenue recognition - Narrative (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2021 USD ($)
Concentration Risk [Line Items]
Number of operating segments | segment		2
Decrease in inventories		$ (57,100,000)	$ (66,600,000)	$ (66,900,000)
Decrease in prepaid expense and other current assets		(19,900,000)	7,700,000	(26,900,000)
Operating lease, lease income, lease payments		4,900,000
Revenue, remaining performance obligation, amount	$ 378,200,000	378,200,000
Contract with customer, asset, after allowance for credit loss, noncurrent	34,800,000	34,800,000	21,500,000
Contract with customer, liability, current	$ 26,400,000	$ 26,400,000	11,700,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Concentration Risk [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	24 months	24 months
Contracts and grants
Concentration Risk [Line Items]
Revenue		$ 41,400,000	134,200,000	115,100,000
Leases
Concentration Risk [Line Items]
Operating lease, lease income, lease payments		4,900,000	305,200,000	278,300,000
Lessor, operating lease, payment to be received, year one	$ 5,100,000	5,100,000
Lessor, operating lease, payment to be received, year two	900,000	900,000
Lessor, operating lease, payment to be received, year three	900,000	900,000
Lessor, operating lease, payment to be received, after year three	2,700,000	2,700,000
USG | Contracts and grants
Concentration Risk [Line Items]
Revenue		37,200,000	130,200,000	109,200,000
USG | Leases
Concentration Risk [Line Items]
Operating lease, lease income, lease payments		0	243,100,000	247,800,000
BARDA
Concentration Risk [Line Items]
Lessor, operating lease, payments to be received				628,200,000	$ 650,800,000
Operating lease, lease income, lease payments			243,100,000	247,800,000
BARDA | Contracts and grants
Concentration Risk [Line Items]
Revenue			$ 71,300,000	15,800,000
BARDA | Reservation Of Manufacturing Capacity
Concentration Risk [Line Items]
Lessor, operating lease, payments to be received				542,700,000
BARDA | Accelerated Expansion Of Fill/Finish Capacity
Concentration Risk [Line Items]
Lessor, operating lease, payments to be received				$ 85,500,000
Jansen Pharmaceuticals, Inc.
Concentration Risk [Line Items]
Decrease in inventories	127,700,000
Decrease in prepaid expense and other current assets	25,000,000
Increase in other assets	152,700,000
Non-cancelable orders	$ 6,200,000	$ 6,200,000
Revenue from Contract with Customer | Customer Concentration Risk | USG
Concentration Risk [Line Items]
Concentration risk percentage		43.00%	51.00%	62.00%
Revenue from Contract with Customer | Customer Concentration Risk | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage		10.00%
United States | Leases
Concentration Risk [Line Items]
Operating lease, lease income, lease payments		$ 0
United States | Revenue from Contract with Customer | Geographic Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage		79.00%	92.00%	93.00%
Non-USG
Concentration Risk [Line Items]
Lessee, operating lease, remaining lease term	2 years 7 months 6 days	2 years 7 months 6 days